KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) EPS (Basic): 2015-2025

Historic EPS (Basic) for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to -$1.17.

  • CRISPR Therapeutics AG's EPS (Basic) fell 15.84% to -$1.17 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.57, marking a year-over-year decrease of 98.93%. This contributed to the annual value of -$4.34 for FY2024, which is 123.71% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported EPS (Basic) of -$1.17 as of Q3 2025, which was up 51.25% from -$2.40 recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's EPS (Basic) ranged from a high of $10.01 in Q2 2021 and a low of -$2.40 during Q2 2022.
  • For the 3-year period, CRISPR Therapeutics AG's EPS (Basic) averaged around -$1.04, with its median value being -$1.17 (2025).
  • Its EPS (Basic) has fluctuated over the past 5 years, first spiked by 870.00% in 2021, then tumbled by 137.17% in 2024.
  • CRISPR Therapeutics AG's EPS (Basic) (Quarterly) stood at -$1.88 in 2021, then increased by 25.53% to -$1.40 in 2022, then soared by 180.71% to $1.13 in 2023, then crashed by 137.17% to -$0.42 in 2024, then decreased by 15.84% to -$1.17 in 2025.
  • Its last three reported values are -$1.17 in Q3 2025, -$2.40 for Q2 2025, and -$1.58 during Q1 2025.